Junge Zhang, Ph.D.
Board
Junge Zhang, Ph.D., serves on the Board of 215 Capital, where he leverages his extensive experience in the biopharmaceutical industry to guide investment strategies and portfolio management.
With over 20 years of pharmaceutical industry experience, Dr. Zhang has been at the forefront of peptide drug development and manufacturing. He has led investments and operations in various aspects of the biopharmaceutical sector, from startups to commercial-stage companies.
Dr. Zhang is the Founder and CEO of Biopeptek Pharmaceuticals, where he has built a state-of-the-art GMP facility. Under his leadership, Biopeptek has become a key player in producing high-quality custom peptides for research and therapeutic applications, collaborating with major pharmaceutical companies and research institutions worldwide.
His expertise spans from drug discovery to FDA approval processes, having led projects that resulted in the approval of three antibody drugs during his tenure at Janssen Pharmaceutical (Johnson & Johnson).
Dr. Zhang founded Mainline Biosciences Inc and Sandigene Inc to discover and develop innovative drugs to cure cancers. Dr. Zhang also founded Mainline Scientific Inc. to develop scientific instruments for drug discovery.
Dr. Zhang serves on the Board of Directors of Ocugen, Inc., a company focused on developing novel gene and cell therapies and vaccines.
Dr. Zhang holds a Ph.D. in Chemistry from Drexel University, an M.S. in Chemistry from the University of Louisiana, and a B.S. from Wuhan University of Technology. His ongoing work continues to drive innovation in drug development and shape investment strategies in the biopharmaceutical sector.
